Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs

Julie Barberio, Timothy L. Lash, Ajay K. Nooka, Ashley I. Naimi, Rachel E. Patzer, Christopher Kim

Blood (2022) 140 (Supplement 1): 4267–4268.

https://doi.org/10.1182/blood-2022-159713

Published: 2022

Journal Articles

A Temporal and Multinational Assessment of Acute Myeloid Leukemia (AML) Cancer Incidence, Survival, and Disease Burden

Laura J. Anderson, Mariam S. Girguis, Ju-Hyeun Kim, Jitesh B. Shewale, Megan Braunlin, Winifred Werther, Juliana E. Hidalgo-Lopez, Faraz Zaman, Christopher Kim

Blood (2021) 138 (Supplement 1): 4124.

https://doi.org/10.1182/blood-2021-146251

Published: 2021

Journal Articles

Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

David S. Ziegler, Van Huynh, Michael J. Burke, Lia Gore, Franco Locatelli, Maureen M. O'Brien, Christopher Kim, Mihaela Obreja, Christopher L. Morris, André Baruchel

Blood (2021) 138 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2021-153865

Published: 2021

Journal Articles

Outcomes of Triple-Class (proteasome inhibitor, immunomodulator, CD38 monoclonal antibody) Exposed Relapsed or Refractory Multiple Myeloma (RRMM) in United States (US) Real-World Practice

Christopher Kim, Megan Braunlin, Bhakti Mehta, Rebecca Payne

Blood (2021) 138 (Supplement 1): 3042.

https://doi.org/10.1182/blood-2021-145588

Published: 2021

Journal Articles

Real World Assessment of Treatment Patterns and Outcomes Among Multiple Myeloma Patients across Different Risk Stratification Criteria in the United States: A Retrospective Cohort Study

Motiur Rahman, Christopher Kim, Jazmine Mateus, Alissa Keegan

Blood (2021) 138 (Supplement 1): 1640.

https://doi.org/10.1182/blood-2021-147439

Published: 2021

Journal Articles

Progression Free Survival of Relapsed or Refractory Multiple Myeloma (RRMM) after Failure of Three Prior Lines of Therapy in United States (US) Real-World Practice

Christopher Kim, PhD, Megan Braunlin, MPH, Rajesh Belani, MD, John Travis Wheeling, MPH

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140549

Published: 2020

Journal Articles

Trends in the Multiple Myeloma Treatment Landscape: A United States Analysis of Oscer Electronic Health Record Data 2011-2019

Megan Braunlin, MPH, Rajesh Belani, MD, Jacqueline Buchanan, John Travis Wheeling, MPH, Christopher Kim, PhD

Blood (2019) 134 (Supplement_1): 4722.

https://doi.org/10.1182/blood-2019-125972

Published: 2019

Journal Articles

Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia

Farhad Ravandi, MD, Sherry A. Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSc, Naval G. Daver, MD, Nicholas J Short, MD, Yesid Alvarado, MD, Jorge E. Cortes, MD, Christopher Kim, PhD, Michael A Kelsh, PhD MPH, MA, Aaron Jacob Katz, PhD PharmD, Richard Williams, MBBS, PhD, Zhao Yang, Bhakti Mehta, MD MPH, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 3985.

https://doi.org/10.1182/blood-2018-99-118380

Published: 2018

Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2018-99-113519

Published: 2018

Journal Articles

Trends in Neutropenia-Related Hospitalization in Older Patients with Non-Hodgkin Lymphoma (NHL) Receiving Myelosuppressive Chemotherapy in the United States: 1995-2015

Shuling Li, PhD, Jiannong Liu, PhD, Haifeng Guo, MS, Prasad L Gawade, MBBS, PhD, Christopher Kim, PhD, Mark E. Bensink, PhD MSc, MD, David Chandler, PhD

Blood (2018) 132 (Supplement 1): 2308.

https://doi.org/10.1182/blood-2018-99-115213

Published: 2018

Journal Articles

Treatment, HSCT Patterns, and Survival of Elderly Diffuse Large B-Cell Lymphoma Patients in the SEER-Medicare Linked Database

Jaime Shaw, MPH, Lauren Johns, PhD, Christopher Harvey, MS, Catherine Richards, PhD, Christopher Kim, PhD

Blood (2018) 132 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2018-99-111051

Published: 2018

Journal Articles

Demographic and Clinical Characteristics of Multiple Myeloma (MM) Patients Treated with Carfilzomib-Based Regimens in a Real World Setting

Christopher Kim, PhD, Winifred Werther, Karim Saad Iskander, Michael Gruber, Khalid Mezzi, MD MBA

Blood (2017) 130 (Supplement 1): 5441.

https://doi.org/10.1182/blood.V130.Suppl_1.5441.5441

Published: 2017

Journal Articles

Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics

Sumita Bhatta, MD, Lori Cyprien, Rafael Fonseca, MD, Rohini K Hernandez, PhD, Christopher Kim, PhD

Blood (2017) 130 (Supplement 1): 2171.

https://doi.org/10.1182/blood.V130.Suppl_1.2171.2171

Published: 2017

Journal Articles

Cross-Sectional Physician Survey on the Use of Minimal Residual Disease (MRD) Testing in the Management of Pediatric and Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Victoria M Chia, PhD MPH, Kara Delaney, BS, Michelle McNamara, Bsc, Christopher Kim, PhD, Vadim Romanov, MD Mphil, FFPM

Blood (2017) 130 (Supplement 1): 5120.

https://doi.org/10.1182/blood.V130.Suppl_1.5120.5120

Published: 2017

Journal Articles

Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data

Christopher Kim, Rohini K. Hernandez, PhD, Paul C Cheng, MD PhD, Jeremy Smith, Lori Cyprien, Alexander Liede, BSc, MSc, PhD

Blood (2016) 128 (22): 2364.

https://doi.org/10.1182/blood.V128.22.2364.2364

Published: 2016

Journal Articles

Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis

Ajai Chari, MD, Sanjay K. Aggarwal, Khalid Mezzi, Kenneth Wang, Christopher Kim, Shao Zhu, Megan Braunlin, Winifred Werther, Joseph Mikhael, MD

Blood (2016) 128 (22): 3319.

https://doi.org/10.1182/blood.V128.22.3319.3319

Published: 2016

Journal Articles

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Sophie Park, MD PhD, Pierre Fenaux, MD PhD, Peter Greenberg, MD, Bhakti Mehta, MD MPH, Fiona Callaghan, PhD, Christopher Kim, PhD MPH, Dianne Tomita, PhD, Hairong Xu, MD PhD

Blood (2015) 126 (23): 5236.

https://doi.org/10.1182/blood.V126.23.5236.5236

Published: 2015

Journal Articles

Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma

Yingtai Chen, Tongzhang Zheng, Qing Lan, Francine Foss, Christopher Kim, Xuezhong Chen, Min Dai, Yumin Li, Theodore Holford, Brian Leaderer, Peter Boyle, Stephen J. Chanock, Nathaniel Rothman, Yawei Zhang

Blood (2011) 117 (2): 585–590.

https://doi.org/10.1182/blood-2010-07-295097

Published: 2011

Includes: Supplemental data

NARROW

Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs

A Temporal and Multinational Assessment of Acute Myeloid Leukemia (AML) Cancer Incidence, Survival, and Disease Burden

Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Outcomes of Triple-Class (proteasome inhibitor, immunomodulator, CD38 monoclonal antibody) Exposed Relapsed or Refractory Multiple Myeloma (RRMM) in United States (US) Real-World Practice

Real World Assessment of Treatment Patterns and Outcomes Among Multiple Myeloma Patients across Different Risk Stratification Criteria in the United States: A Retrospective Cohort Study

Progression Free Survival of Relapsed or Refractory Multiple Myeloma (RRMM) after Failure of Three Prior Lines of Therapy in United States (US) Real-World Practice

Trends in the Multiple Myeloma Treatment Landscape: A United States Analysis of Oscer Electronic Health Record Data 2011-2019

Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Trends in Neutropenia-Related Hospitalization in Older Patients with Non-Hodgkin Lymphoma (NHL) Receiving Myelosuppressive Chemotherapy in the United States: 1995-2015

Treatment, HSCT Patterns, and Survival of Elderly Diffuse Large B-Cell Lymphoma Patients in the SEER-Medicare Linked Database

Demographic and Clinical Characteristics of Multiple Myeloma (MM) Patients Treated with Carfilzomib-Based Regimens in a Real World Setting

Multiple Myeloma Patients and Risk of Skeletal Related Events - Real-World Evidence in US Oncology Clinics

Cross-Sectional Physician Survey on the Use of Minimal Residual Disease (MRD) Testing in the Management of Pediatric and Adult Patients with Acute Lymphoblastic Leukemia (ALL)

Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data

Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis

Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis

Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only